CA2836851C - Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors - Google Patents

Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors Download PDF

Info

Publication number
CA2836851C
CA2836851C CA2836851A CA2836851A CA2836851C CA 2836851 C CA2836851 C CA 2836851C CA 2836851 A CA2836851 A CA 2836851A CA 2836851 A CA2836851 A CA 2836851A CA 2836851 C CA2836851 C CA 2836851C
Authority
CA
Canada
Prior art keywords
alkyl
methyl
compound
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2836851A
Other languages
English (en)
French (fr)
Other versions
CA2836851A1 (en
Inventor
Christopher J. Helal
Thomas Allen Chappie
John M. Humphrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CA2836851A1 publication Critical patent/CA2836851A1/en
Application granted granted Critical
Publication of CA2836851C publication Critical patent/CA2836851C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2836851A 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors Expired - Fee Related CA2836851C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494070P 2011-06-07 2011-06-07
US61/494,070 2011-06-07
PCT/IB2012/052627 WO2012168817A1 (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Publications (2)

Publication Number Publication Date
CA2836851A1 CA2836851A1 (en) 2012-12-13
CA2836851C true CA2836851C (en) 2016-06-21

Family

ID=46298646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836851A Expired - Fee Related CA2836851C (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Country Status (11)

Country Link
US (1) US8829010B2 (enExample)
EP (1) EP2718295A1 (enExample)
JP (1) JP2014516074A (enExample)
KR (1) KR101626681B1 (enExample)
CN (1) CN103596956A (enExample)
AU (1) AU2012265970A1 (enExample)
CA (1) CA2836851C (enExample)
IL (1) IL229606A0 (enExample)
MX (1) MX2013014470A (enExample)
SG (1) SG195085A1 (enExample)
WO (1) WO2012168817A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2014126954A1 (en) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Regioselective synthesis of substituted pyrimidines
CN104098574A (zh) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 氮杂环丁烷取代嘧啶类化合物及其用途
WO2015026646A1 (en) * 2013-08-20 2015-02-26 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
MA50375A (fr) 2014-04-23 2021-05-26 Dart Neuroscience Cayman Ltd Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
AU2015357496B2 (en) * 2014-12-06 2019-09-19 Intra-Cellular Therapies, Inc. Organic compounds
KR102562576B1 (ko) 2014-12-06 2023-08-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2018091687A1 (en) 2016-11-18 2018-05-24 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN111447930A (zh) 2017-11-23 2020-07-24 奥斯陆大学医院公司 心动过速的治疗
BR112022008786A2 (pt) * 2019-11-09 2022-07-26 Shanghai Simr Biotechnology Co Ltd Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
CN101103033B (zh) * 2005-01-05 2010-08-04 尼科梅德有限责任公司 作为pde2抑制剂的三唑并酞嗪
CN102491969B (zh) 2005-01-07 2015-08-19 辉瑞产品公司 杂芳族喹啉化合物及其作为pde10抑制剂的用途
CN102020645B (zh) * 2010-09-30 2012-12-12 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用

Also Published As

Publication number Publication date
MX2013014470A (es) 2014-03-21
EP2718295A1 (en) 2014-04-16
US20140080806A1 (en) 2014-03-20
CA2836851A1 (en) 2012-12-13
KR101626681B1 (ko) 2016-06-01
US8829010B2 (en) 2014-09-09
AU2012265970A1 (en) 2013-11-28
JP2014516074A (ja) 2014-07-07
WO2012168817A1 (en) 2012-12-13
CN103596956A (zh) 2014-02-19
IL229606A0 (en) 2014-01-30
KR20140019466A (ko) 2014-02-14
SG195085A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
CA2836851C (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
US8598155B2 (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
EP3419978B1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CA2661334C (en) Pyrimidone compounds as gsk-3 inhibitors
AU2012221828A1 (en) Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders
US9422271B2 (en) Pyrimidine compounds as tuberculosis inhibitors
US11345681B1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN115209952B (zh) 经取代的吡唑并嘧啶及其用途
US11814384B2 (en) Inhibtors of Raf kinases
HK1193814A (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
HK40085563A (en) Inhibitors of fibroblast growth factor receptor kinases
NZ613373B2 (en) IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
OA18860A (en) Pyrazolo[1,5-A)pyrazin-4-yl derivatives as Jak-inhibitors
HK1188990A (en) IMIDAZO[5, 1-ƒ][1,2-4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131120

MKLA Lapsed

Effective date: 20180524